First blood-based biomarker in response to the treatment of the most aggressive prostate cancer

0

(Centro Nacional de Investigaciones Oncológicas (CNIO)) In castration-resistant prostate cancer, the tumors continue to progress even though testosterone production has been blocked; more than 90% of these patients develop metastasis and the survival rate is one to two years.* Using liquid biopsy, a simple blood test has been successful in determining what type of treatment can help to prolong the life expectancy of more than 150 patients

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More